Gene screening and prevention of hereditary breast cancer: a cost-effectiveness Monte-Carlo study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68407700%3A21460%2F13%3A00205725" target="_blank" >RIV/68407700:21460/13:00205725 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Gene screening and prevention of hereditary breast cancer: a cost-effectiveness Monte-Carlo study

Popis výsledku v původním jazyce

BACKGROUND: The hereditary syndrome (BRCA1/BRCA2 mutations) causes 5?7% of diagnosed breast cancer. In Czech Republic, patients suspected of this gene alteration undergo DNA testing, and the whole family joins screening programs. They will eventually become ill with a high probability (predicted breast cancer risk in women with BRCA1/BRCA2 mutation being 78-83% by the age of 70), however, the screening can detect cancer in earlier stages. The screening program has run only for 10 years comprising 105 patients, 10 diagnosed with breast cancer. Although the outcome in these women was better than in the general population, cost/QALY appeared higher for preventive programs. The reasons might have been the size of the sample. OBJECTIVE: To assess cost effectiveness of hereditary breast cancer prevention as standard care in family members of diagnosed patients. METHODS: Due to the lack of clinical data, calculations were repeated using a cohort of patients generated by the Monte-Carlo method

Název v anglickém jazyce

Gene screening and prevention of hereditary breast cancer: a cost-effectiveness Monte-Carlo study

Popis výsledku anglicky

BACKGROUND: The hereditary syndrome (BRCA1/BRCA2 mutations) causes 5?7% of diagnosed breast cancer. In Czech Republic, patients suspected of this gene alteration undergo DNA testing, and the whole family joins screening programs. They will eventually become ill with a high probability (predicted breast cancer risk in women with BRCA1/BRCA2 mutation being 78-83% by the age of 70), however, the screening can detect cancer in earlier stages. The screening program has run only for 10 years comprising 105 patients, 10 diagnosed with breast cancer. Although the outcome in these women was better than in the general population, cost/QALY appeared higher for preventive programs. The reasons might have been the size of the sample. OBJECTIVE: To assess cost effectiveness of hereditary breast cancer prevention as standard care in family members of diagnosed patients. METHODS: Due to the lack of clinical data, calculations were repeated using a cohort of patients generated by the Monte-Carlo method

Druh

O - Ostatní výsledky

CEP obor

FQ - Veřejné zdravotnictví, sociální lékařství

OECD FORD obor

—

Projekt

<a href="/cs/project/NT11532" target="_blank" >NT11532: Hodnocení zdravotnických prostředků</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů